Then, we observed that the p53 rs1042522 polymorphism reduced the risk of cervical cancer in the matching studies (Pro/Pro +Arg/Pro vs. Arg/Arg: OR = 0.78, 95% CI = 0.68-0.90; Pro/Pro vs. Arg/Arg: OR = 0.75, 95% CI = 0.63-0.90; Arg/Pro vs. Arg/Arg: OR = 0.79, 95% CI = 0.68-0.91; Pro vs. Arg: OR = 0.88, 95% CI = 0.80-0.97, Table 1) and non-matching studies (Pro/Pro +Arg/Pro vs. Arg/Arg: OR = 0.79, 95% CI = 0.68-0.91; Pro/Pro vs. Arg/Arg: OR = 0.83, 95% CI = 0.74-0.94; Arg/Pro vs. Arg/Arg: OR = 0.78, 95% CI = 0.68-0.90; Pro vs. Arg: OR = 0.86, 95% CI =0.77-0.96, Table 1). This evidence concerns the gene TP53 and cervical cancer.